ClinicalTrials.gov
public full text
Public Domain
First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers
This is an adaptive, randomised, double-blind, single-centre, placebo-controlled phase I, First in Human study designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple intravenous dosing of ANXV in healthy male subjects.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis#1372686
- Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease#905869
- All-Case Surveillance of Ofev in Patients With IPF in Japan#803516
- An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005#887819
- Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults#1095186
Record · ID 1230605
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive